OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
January 03, 2024
Buffers, stabilizers, and cryoprotectants play major roles in cell therapy formulations.
December 29, 2023
Through Syena, its oncology-focused product company, Replay will develop and manufacture T-cell receptor and natural killer cell therapies with the NIH and Miltenyi Biotec.
December 28, 2023
Tome Bioscience is facilitating the transition in biology from the editing phase to the cut-and-paste phase.
December 20, 2023
Under a collaboration, Daiichi Sankyo and Depixus will use Depixus’ MAGNA technology to accelerate drug discovery efforts of RNA-targeted therapeutics.
December 19, 2023
Bristol Myers Squibb and SystImmune plan to co-develop and co-commercialize lead ADC candidate for cancer treatment in US.
December 18, 2023
Technical, regulatory, and personnel considerations characterize pharmaceutical compounding.
December 13, 2023
The new advisory committee will provide the agency with technical and scientific advice and recommendations on potential treatments for genetic metabolic diseases.
December 05, 2023
AstraZeneca will utilize Absci’s AI antibody drug creation platform to create an AI-designed antibody.
December 03, 2023
Matching excipients to API properties is essential.
Collaboration is a key component to achieving long-term success with genetic medicines.